Lamberti P - Search Results

1

Lamberti P, Armenise S, Castaldo V, de Mari M, Iliceto G, Tronci P, Serlenga L. Lamberti P, et al. Eur Neurol. 1997;38(4):297-301. doi: 10.1159/000113398. Eur Neurol. 1997. PMID: 9434089

2

Dopa responsive dystonia and juvenile Parkinson's disease: two subtypes of the same disorder?

Lamberti P, de Mari M, Iliceto G, Federico F. Lamberti P, et al. Acta Neurol (Napoli). 1992 Aug-Dec;14(4-6):451-4. Acta Neurol (Napoli). 1992. PMID: 1293988

3

Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.

Lamberti P, Zoccolella S, Armenise E, Lamberti SV, Fraddosio A, de Mari M, Iliceto G, Livrea P. Lamberti P, et al. Among authors: lamberti sv. Eur J Neurol. 2005 May;12(5):365-8. doi: 10.1111/j.1468-1331.2004.00973.x. Eur J Neurol. 2005. PMID: 15804266

4

Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy.

Federico F, Simone IL, Lucivero V, De Mari M, Giannini P, Iliceto G, Mezzapesa DM, Lamberti P. Federico F, et al. Among authors: lamberti p. J Neurol Neurosurg Psychiatry. 1997 Mar;62(3):239-42. doi: 10.1136/jnnp.62.3.239. J Neurol Neurosurg Psychiatry. 1997. PMID: 9069478 Free PMC article. Clinical Trial.

5

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.

Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, Livrea P. Lamberti P, et al. Mov Disord. 2005 Jan;20(1):69-72. doi: 10.1002/mds.20261. Mov Disord. 2005. PMID: 15390046 Clinical Trial.

6

Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.

Zoccolella S, Lamberti P, Iliceto G, Diroma C, Armenise E, Defazio G, Lamberti SV, Fraddosio A, de Mari M, Livrea P. Zoccolella S, et al. Among authors: lamberti sv, lamberti p. Clin Chem Lab Med. 2005;43(10):1107-10. doi: 10.1515/CCLM.2005.193. Clin Chem Lab Med. 2005. PMID: 16197306

7

Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias.

Zoccolella S, Lamberti P, Iliceto G, Dell'Aquila C, Diroma C, Fraddosio A, Lamberti SV, Armenise E, Defazio G, de Mari M, Livrea P. Zoccolella S, et al. Among authors: lamberti sv, lamberti p. Clin Chem Lab Med. 2006;44(7):863-6. doi: 10.1515/CCLM.2006.143. Clin Chem Lab Med. 2006. PMID: 16776634

8

Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.

Nicoletti A, Mostile G, Nicoletti G, Arabia G, Iliceto G, Lamberti P, Marconi R, Morgante L, Barone P, Quattrone A, Zappia M. Nicoletti A, et al. Among authors: lamberti p. J Neurol. 2016 May;263(5):888-894. doi: 10.1007/s00415-016-8075-6. Epub 2016 Mar 10. J Neurol. 2016. PMID: 26964541

9

Intravenous administration of lisuride in the treatment of neuroleptic malignant syndrome.

de Mari M, Lamberti P, Simone F, Iliceto G, Federico F, Ferrari E. de Mari M, et al. Among authors: lamberti p. Funct Neurol. 1991 Jul-Sep;6(3):285-8. Funct Neurol. 1991. PMID: 1683852

10

Short-latency median nerve somatosensory evoked potentials in three cases of parkinsonism and dopa responsive dystonia.

Margari L, de Mari M, Lamberti P, Iliceto G, Serlenga L, Perniola T, Rossini PM, Ferrari E. Margari L, et al. Among authors: lamberti p. Funct Neurol. 1995 Mar-Apr;10(2):99-105. Funct Neurol. 1995. PMID: 7557558

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

180 results

Search Page

Filters